Document is current

Article History

Received: 1 November 2021

Accepted: 27 December 2021

First Online: 7 February 2022

Declarations

:

: This trial was approved by regulatory and independent ethics committee at all participating sites and all patients had consented to participate in this trial.

: Not applicable.

: PJV: None.EXC: Honoraria from Taiho, Bayer, and Eisai; institution funding for clinical trials from AZ, BMS, Merck, Zymeworks, and Novartis.HXC: None.ACL: Consulting role for Novartis.KK: Clinical trial support from Novartis for upcoming capmatinib study.UNV: Research funding from Merck and Bristol Myers Squibb. Consulting fees and Honoraria from Merck, Bayer, BMS, AAA, Pfizer, Exelixis Inc.SS: Research funding from Merck, Bristol Myers Squibb and Brooklyn ImmunoTherapeutics; Advisory Board: Merck and Boehringer Ingelheim.VS: Grants or research support from Novartis, AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, Berghealth, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, D3 Pharma, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharmaceuticals, Incyte, Inhibrx, Loxo Oncology, MedImmune, MultiVir, National Comprehensive Cancer Network, NCI-Cancer Therapy Evaluation Program, Novartis, Pfizer, PharmaMar, Takeda, The University of Texas MD Anderson Cancer Center, and Turning Point Therapeutics and advisory/board member role in Eli Lilly, Helsinn, Incyte, Relay Therapeutics, Loxo Oncology, MedImmune, Novartis, QED Therapeutics, and R-Pharma US.DJR: Research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and Astra Zeneca.ARR: Consulting/advisory roles for Eli-Lilly, Medison, GSK, Merck, Bayer, and Adaptimmune; institutional research funding from Boerhinger-Ingelheim, Eli-Lilly, Boston Biomedicals, Deciphera, Karyopharm Therapeutics, Pfizer, Roche/Genentech, BMS, Medimmune, Amgen, GSK, Blueprint Medicines, Symphogen, Merck, AbbVie, Adaptimmune, and Iterion Therapeutics.SPI: None.SJH: None.AS (Singh): None.PLB: Consulting/advisory arrangements (uncompensated) with BristolMyersSquibb, Sanofi, Pfizer, Genentech/Roche, Amgen, Lilly, SeaGen, Merck, and Gilead; and institution receives clinical trials supports from Novartis, BristolMyersSquibb, Sanofi, Genentech/Roche, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, SeaGen, Sanofi, Mersana, Amgen, Zymeworks, VelosBio, Bicara Therapeutics, AstraZeneca, and Pfizer.ARH: Research and Consulting: Genentech Inc., Hoffmann La Roche Inc., Merck Serono S.A., GlaxoSmithKline Inc., Bristol-Myers Squibb Company, Novartis Pharmaceuticals Canada Inc., Boehringer Ingelheim International GmbH, AstraZeneca Pharmaceuticals LP, MedImmune LL and Pfizer Inc.LW: None.LAS: None.LLS: Consulting/advisory arrangements with Merck, Pfizer, Celgene, AstraZeneca, Morphosys, Roche, Oncorus, Symphogen, Seattle Genetics, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Rubius, Janpix, Daiichi Sanyko; stock ownership of Agios (spouse); leadership position in Treadwell Therapeutics (spouse); and institution receives clinical trials support from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks, Avid.AS: Consulting/advisory arrangements within the last 5 years include: Merck, Bristol-Myers Squibb, Oncorus, Janssen. The institution receives clinical trial funding support from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Treadwell.